Publications by authors named "S J d'Arcy"

Article Synopsis
  • The TRAMP complex is crucial for RNA processing and features two key enzymatic activities that involve both polyadenylation and unwinding of RNA.
  • New research using hydrogen-deuterium exchange data reveals insights into how TRAMP assembles and shuffles RNA between its catalytic sites, which are not fully understood.
  • Findings indicate that peripheral RNA-recognition motifs affect TRAMP assembly and that different active-site subunits interact with tRNA in ways that influence RNA transfer between TRAMP components.
View Article and Find Full Text PDF

The TRAMP complex contains two enzymatic activities essential for RNA processing upstream of the nuclear exosome. Within TRAMP, RNA is 3' polyadenylated by a sub-complex of Trf4/5 and Air1/2 and unwound 3' to 5' by Mtr4, a DExH helicase. The molecular mechanisms of TRAMP assembly and RNA shuffling between the two TRAMP catalytic sites are poorly understood.

View Article and Find Full Text PDF

Laboratory evolution studies have demonstrated that parallel evolutionary trajectories can lead to genetically distinct enzymes with high activity towards a non-preferred substrate. However, it is unknown whether such enzymes have convergent conformational dynamics and mechanistic features. To address this question, we use as a model the wild-type Homo sapiens kynureninase (HsKYNase), which is of great interest for cancer immunotherapy.

View Article and Find Full Text PDF

Variants in the poorly characterised oncoprotein, MORC2, a chromatin remodelling ATPase, lead to defects in epigenetic regulation and DNA damage response. The C-terminal domain (CTD) of MORC2, frequently phosphorylated in DNA damage, promotes cancer progression, but its role in chromatin remodelling remains unclear. Here, we report a molecular characterisation of full-length, phosphorylated MORC2, demonstrating its preference for binding open chromatin and functioning as a DNA sliding clamp.

View Article and Find Full Text PDF
Article Synopsis
  • Camizestrant, an oral selective estrogen receptor degrader (SERD), shows enhanced efficacy in treating estrogen receptor-positive (ER+) breast cancer compared to existing therapies, effectively targeting resistant cancer cells.
  • In preclinical studies, camizestrant demonstrated significant ER degradation and antiproliferative effects in various breast cancer models, including those resistant to current treatments like fulvestrant.
  • Combining camizestrant with CDK4/6 inhibitors and PI3K/AKT/mTOR-targeted therapies increased antitumor effectiveness, suggesting a powerful approach to overcoming endocrine resistance in breast cancer patients.
View Article and Find Full Text PDF